CN107108721B - 包含hiv-1包膜靶向臂的双特异性分子 - Google Patents

包含hiv-1包膜靶向臂的双特异性分子 Download PDF

Info

Publication number
CN107108721B
CN107108721B CN201580063039.0A CN201580063039A CN107108721B CN 107108721 B CN107108721 B CN 107108721B CN 201580063039 A CN201580063039 A CN 201580063039A CN 107108721 B CN107108721 B CN 107108721B
Authority
CN
China
Prior art keywords
seq
domain
hiv
cells
polypeptide chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580063039.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107108721A (zh
Inventor
B·F·海恩斯
G·法拉利
S·凯尼格
L·S·约翰逊
郭家颖
J·A·宋
D·M·马戈利斯
刘丽勤
J·L·诺德斯特姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Macrogenics Inc
Duke University
Original Assignee
University of North Carolina at Chapel Hill
Macrogenics Inc
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Macrogenics Inc, Duke University filed Critical University of North Carolina at Chapel Hill
Publication of CN107108721A publication Critical patent/CN107108721A/zh
Application granted granted Critical
Publication of CN107108721B publication Critical patent/CN107108721B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580063039.0A 2014-09-29 2015-09-29 包含hiv-1包膜靶向臂的双特异性分子 Expired - Fee Related CN107108721B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462056834P 2014-09-29 2014-09-29
US62/056,834 2014-09-29
US201562206586P 2015-08-18 2015-08-18
US62/206,586 2015-08-18
PCT/US2015/053027 WO2016054101A1 (en) 2014-09-29 2015-09-29 Bispecific molecules comprising an hiv-1 envelope targeting arm

Publications (2)

Publication Number Publication Date
CN107108721A CN107108721A (zh) 2017-08-29
CN107108721B true CN107108721B (zh) 2021-09-07

Family

ID=55631387

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580063039.0A Expired - Fee Related CN107108721B (zh) 2014-09-29 2015-09-29 包含hiv-1包膜靶向臂的双特异性分子

Country Status (12)

Country Link
US (2) US10717778B2 (enExample)
EP (1) EP3201227A4 (enExample)
JP (1) JP6932639B2 (enExample)
CN (1) CN107108721B (enExample)
AU (1) AU2015323860B2 (enExample)
BR (1) BR112017006515A8 (enExample)
CA (1) CA2963991A1 (enExample)
IL (1) IL251437B (enExample)
MX (1) MX386297B (enExample)
SG (1) SG11201702544WA (enExample)
WO (1) WO2016054101A1 (enExample)
ZA (1) ZA201702235B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI706960B (zh) * 2014-09-26 2020-10-11 美商宏觀基因股份有限公司 能夠結合cd19和cd3的雙特異性雙抗體及其用途
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
EP3463464A4 (en) 2016-06-07 2020-07-01 MacroGenics, Inc. ASSOCIATION TREATMENT
WO2018053328A1 (en) * 2016-09-16 2018-03-22 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
CN108728463A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达IgG抗体的微环DNA载体及其制备方法和应用
SG11202005557TA (en) * 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
AU2019222666B2 (en) 2018-02-15 2025-12-04 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
CA3100398A1 (en) * 2018-05-18 2019-11-21 Macrogenics, Inc. Optimized gp41-binding molecules and uses thereof
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
WO2014052620A1 (en) * 2012-09-26 2014-04-03 Duke University Adcc-mediating antibodies, combinations and uses thereof

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (enExample) 1974-03-08 1982-06-04
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4752601A (en) 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5364930A (en) 1990-10-16 1994-11-15 Northwestern University Synthetic C1q peptide fragments
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
PT682710E (pt) 1993-02-10 2004-03-31 Unilever Nv Processo de isolamento utilizando proteinas imobilizadas com capacidades de ligacao especificas
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
EP0711303B2 (en) 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
ATE204300T1 (de) 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6025485A (en) 1997-02-14 2000-02-15 Arcaris, Inc. Methods and compositions for peptide libraries displayed on light-emitting scaffolds
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
ATE427966T1 (de) 1997-02-11 2009-04-15 Immunomedics Inc Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
JP2002505086A (ja) 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション 抗体ベースの融合タンパク質の循環半減期の増強
US6455263B2 (en) 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
SE9802213D0 (sv) 1998-06-18 1998-06-18 Amersham Pharm Biotech Ab A method for the removal/purification of serum albumins and means for use in the method
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US7315786B2 (en) 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
DE19937264A1 (de) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
DE60130538T2 (de) 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
US20040038339A1 (en) 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
JP4229704B2 (ja) 2001-04-18 2009-02-25 ダイアックス、コープ Ｆｃ領域ポリペプチドの結合分子
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP2316485A1 (en) 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
EP1450857B1 (en) 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20050142539A1 (en) 2002-01-14 2005-06-30 William Herman Targeted ligands
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
CA2484182A1 (en) 2002-04-29 2003-11-13 Genpat77 Pharmacogenetics Ag Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
JP2006512050A (ja) 2002-06-21 2006-04-13 ダイアックス、コープ 血清タンパク質結合標的特異的リガンドとその同定方法
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2272533A1 (en) 2003-01-13 2011-01-12 MacroGenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
DE10346627A1 (de) 2003-10-08 2005-05-19 Weiss, Stefan, PD Dr. Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
ATE437184T1 (de) 2004-01-12 2009-08-15 Applied Molecular Evolution Varianten der fc-region
EA011583B1 (ru) 2004-03-31 2009-04-28 Сентокор, Инк. Миметические антитела glp-1 человека, композиции, способы и применения
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
MXPA06011796A (es) 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
US7521542B2 (en) 2004-05-10 2009-04-21 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
US7432419B2 (en) 2004-05-14 2008-10-07 Los Alamos National Security, Llc Compositions and methods for the treatment of Pierce's disease
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
US20080038280A1 (en) 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20060193849A1 (en) 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
WO2006137931A2 (en) 2005-03-14 2006-12-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serivces Human monoclonal antibodies against hendra and nipah viruses
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
EP3770174A1 (en) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
JP5427027B2 (ja) 2006-05-03 2014-02-26 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
EP2019857B1 (en) 2006-05-03 2016-09-28 The Regents of the University of Colorado, a body corporate Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
ATE490249T1 (de) 2007-02-19 2010-12-15 Glaxosmithkline Llc Purinderivate als immunmodulatoren
MX2009013816A (es) 2007-06-21 2010-02-24 Macrogenics Inc Diacuerpos covalentes y usos de los mismos.
EP2210112B1 (en) 2007-10-15 2012-02-08 King's College London Diagnostic methods for hiv infection
MX2010004892A (es) 2007-10-31 2010-08-10 Scripps Research Inst Terapia de combinacion para tratar infecciones virales persistentes.
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
EP2698380A1 (en) 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralizing molecules to viral antigens
PT2247304T (pt) 2008-04-02 2016-08-29 Macrogenics Inc Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US20100040601A1 (en) 2008-06-10 2010-02-18 Cantin Edouard M Compositions and methods for treating herpes simplex virus infections and related diseases
EP3482769B1 (en) 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
US8211866B2 (en) 2009-01-14 2012-07-03 Children's Research Institute, Children's National Medical Center Methods and compositions for treating HIV infection
EP2406387A4 (en) 2009-03-09 2013-04-17 Tvax Biomedical I Llc CELL IMMUNOTHERAPY FOR INFECTION DISEASES
US20110033389A1 (en) 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
CA2764398A1 (en) 2009-06-05 2010-12-09 Erik Depla Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
ES2865648T3 (es) 2009-06-26 2021-10-15 Regeneron Pharma Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
US8999398B2 (en) 2009-11-06 2015-04-07 Transtarget Inc. Polyclonal bispecific antibody compositions and method of use
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
ES2540114T3 (es) 2010-07-09 2015-07-08 Affibody Ab Polipéptidos
CN103154025B (zh) 2010-08-02 2015-07-01 宏观基因有限公司 共价双抗体及其用途
EP4549461A3 (en) 2010-08-31 2025-08-06 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
JP2014500712A (ja) 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
RU2013140685A (ru) 2011-02-04 2015-03-10 Дженентек, Инк. ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
AU2012265156B2 (en) 2011-05-27 2017-01-19 F. Hoffmann-La Roche Ag Dual targeting
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US9879068B2 (en) 2012-06-21 2018-01-30 California Institute Of Technology Antibodies targeting HIV escape mutants
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EP2968520B1 (en) 2013-03-14 2021-05-12 MacroGenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
WO2015048462A1 (en) * 2013-09-27 2015-04-02 Duke University Human monoclonal antibodies
SG10201913324PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
TWI706960B (zh) * 2014-09-26 2020-10-11 美商宏觀基因股份有限公司 能夠結合cd19和cd3的雙特異性雙抗體及其用途
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
WO2014052620A1 (en) * 2012-09-26 2014-04-03 Duke University Adcc-mediating antibodies, combinations and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Elimination of Latently HIV-1-lnfected Cells by Lymphoblasts Armed with Bifunctional Antibody;Shuping Yin等;《Microbiol.Immunol.》;20131114;第45卷(第1期);摘要部分 *

Also Published As

Publication number Publication date
MX2017004076A (es) 2017-07-04
AU2015323860B2 (en) 2021-05-27
EP3201227A1 (en) 2017-08-09
JP2017534296A (ja) 2017-11-24
BR112017006515A8 (pt) 2018-02-27
JP6932639B2 (ja) 2021-09-08
WO2016054101A1 (en) 2016-04-07
EP3201227A4 (en) 2018-04-18
CN107108721A (zh) 2017-08-29
SG11201702544WA (en) 2017-04-27
IL251437B (en) 2021-02-28
IL251437A0 (en) 2017-05-29
MX386297B (es) 2025-03-18
BR112017006515A2 (pt) 2017-12-19
AU2015323860A1 (en) 2017-05-11
CA2963991A1 (en) 2016-04-07
US20200354439A1 (en) 2020-11-12
US12173051B2 (en) 2024-12-24
US20180148497A1 (en) 2018-05-31
ZA201702235B (en) 2021-09-29
US10717778B2 (en) 2020-07-21

Similar Documents

Publication Publication Date Title
CN107108721B (zh) 包含hiv-1包膜靶向臂的双特异性分子
JP7662516B2 (ja) Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用
US12448423B2 (en) Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains
KR102324568B1 (ko) HIV gp120 및 CD3을 표적화하는 다중특이적 항체
Sung et al. Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells
US20230340130A1 (en) Multi-specific binding proteins for cancer treatment
US10344077B2 (en) HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
KR20230054508A (ko) 이중특이적 체크포인트 억제제 항체
IL301140A (en) Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection
Moldt et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV
Richardson et al. HIV broadly neutralizing antibodies expressed as IgG3 preserve neutralization potency and show improved Fc effector function
WO2017011413A1 (en) Bispecific molecules comprising an hiv-1 envelope targeting arm
TW202348625A (zh) 靶向hiv之多特異性抗原結合分子及使用方法
WO2017011414A1 (en) Bispecific molecules comprising an hiv-1 envelope targeting arm
Rujas et al. Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity
CN118251411A (zh) 抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2016054023A1 (en) Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
CN112533945A (zh) 优化的结合gp41的分子及其用途
JP2025525886A (ja) Ｃｄ２８に対する多機能性分子
TW202241967A (zh) 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物
WO2018053328A1 (en) Bispecific molecules comprising an hiv-1 envelope targeting arm
Winnall et al. The maturation of antibody technology for the HIV epidemic
JP2024525691A (ja) 最適化されたＭｕｌｔａｂｏｄｙ構築物、組成物、及び方法
US20220017453A2 (en) Igm compositions and methods of mucosal delivery of these compositions
WO2024206190A1 (en) Antibodies that target hla-e-host peptide complexes and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210907

CF01 Termination of patent right due to non-payment of annual fee